Soleno Therapeutics Soars 26% on Acquisition Talks with Neurocrine Biosciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy SLNO?
Source: Yahoo Finance
- Acquisition Talks Progress: Neurocrine Biosciences is in advanced discussions to acquire Soleno Therapeutics, with the deal potentially valued at over $2.5 billion, leading to a 26% surge in premarket trading, reflecting strong market optimism about the transaction.
- Market Opportunity: Should the acquisition proceed, Neurocrine would gain access to Soleno's treatment for Prader-Willi syndrome, which analysts project could generate up to $2.3 billion in peak annual sales, enhancing the strategic appeal of the acquisition.
- Price Target Analysis: The anticipated acquisition price is in the range of $50 to $60 per share, indicating investor confidence in Soleno's future growth potential while providing Neurocrine with an opportunity to enter new markets.
- Warning Signals: Despite the stock surge, GuruFocus has flagged 4 warning signs for Soleno, advising investors to cautiously assess its true value to avoid potential investment risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.510
Low
75.00
Averages
110.50
High
125.00
Current: 52.510
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a securities class action lawsuit with a lead plaintiff deadline of May 5, 2026, affecting those who purchased shares between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety risks associated with its flagship product, VYKAT™ XR (DCCR), including serious concerns such as excess fluid retention and potential heart failure in children, which could severely impact the company's credibility and stock performance.
- Data Integrity Issues: A report by activist short seller Scorpion Capital highlighted that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed irregularities, raising serious questions about the integrity of the company's claims and potentially undermining investor confidence.
- Stock Price Plunge: Following Soleno's admission on November 4, 2025, of disruptions in DCCR's launch trajectory, the stock plummeted 27% in a single day, reflecting the market's deep concerns regarding the company's future prospects and operational viability.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share in cash, which may infringe on shareholder rights, prompting shareholders to understand their legal rights and options.
- Complex Transaction Terms: Thermon Group Holdings, Inc. (NYSE:THR) is proposed to be sold to CECO Environmental Corp., where shareholders can choose between $10.00 in cash plus 0.6840 shares of CECO stock, $63.89 per share, or 0.8110 shares of CECO stock, potentially affecting the final returns for shareholders.
- Cash Acquisition Proposal: Affinity Bancshares, Inc. (NASDAQ:AFBI) plans to sell to Fidelity BancShares (N.C.) for $23.00 per share in cash, subject to adjustments based on the adjusted stockholders' equity at closing, adding uncertainty to the transaction.
- Shareholder Rights Protection: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief measures to protect shareholder rights and address potential securities fraud issues.
See More
Multiple Companies Facing Class Action Lawsuits
- Eos Energy Lawsuit: Eos Energy Enterprises is facing allegations for failing to meet production and capacity utilization targets during the period from November 5, 2025, to February 26, 2026, which has severely undermined investor confidence and is expected to negatively impact its stock performance.
- Soleno Therapeutics Issues: Soleno Therapeutics is under scrutiny for concealing safety concerns related to its DCCR clinical trial from March 26, 2025, to November 4, 2026, potentially jeopardizing the commercial viability of its product and eroding investor trust and market performance.
- Nektar Therapeutics Allegations: Nektar Therapeutics faces accusations of not adhering to applicable standards in its REZOLVE-AA trial from February 26, 2025, to December 15, 2025, which may compromise the integrity of trial results and adversely affect the company's reputation and stock price.
- Driven Brands Financial Errors: Driven Brands is being sued for multiple financial reporting errors from May 3, 2023, to February 24, 2026, which could lead to a decline in investor confidence regarding the company's financial health, thereby impacting its market performance.
See More
Soleno Therapeutics Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns regarding its DCCR drug during clinical trials, including issues like fluid retention in participants, which led to investor losses once the true information was disclosed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong expertise and track record in this field.
- Investor Guidance: The firm advises investors to select counsel with proven success to avoid partnering with firms that merely act as intermediaries, ensuring they receive the best representation and support in the class action process.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Soleno Therapeutics in the Northern District of California on behalf of investors who purchased shares between March 26 and November 4, 2025, alleging the company failed to disclose safety concerns related to its DCCR drug, resulting in investor losses.
- Allegation Details: The complaint claims that Soleno systematically downplayed and concealed significant safety issues associated with DCCR, including fluid retention in trial participants, which materially affected the drug's commercial viability and posed greater risks than disclosed.
- Investor Losses: Investors suffered significant damages when the true details emerged, and the lawsuit seeks accountability from Soleno, with a deadline of May 5, 2026, for investors to apply to be lead plaintiffs in the case.
- Legal Consultation Opportunity: Bragar Eagel & Squire encourages affected investors to reach out for discussions about their legal rights, offering no-cost consultations to ensure investors understand their rights and potential legal avenues.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ:SLNO) is facing a securities class action lawsuit, with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26, 2025, and November 4, 2025, and suffered significant losses.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed safety risks associated with its flagship product, VYKAT™ XR (DCCR), and used questionable metrics to maintain an inflated stock price, resulting in investor losses.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 financial results, admitting to disruptions in DCCR's launch trajectory, leading to a 27% drop in stock price on the same day, reflecting market disappointment in the company's outlook.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% for original information that aids in the investigation, aiming to protect investor interests.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a securities class action lawsuit with a lead plaintiff deadline of May 5, 2026, affecting those who purchased shares between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety risks associated with its flagship product, VYKAT™ XR (DCCR), including serious concerns such as excess fluid retention and potential heart failure in children, which could severely impact the company's credibility and stock performance.
- Data Integrity Issues: A report by activist short seller Scorpion Capital highlighted that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed irregularities, raising serious questions about the integrity of the company's claims and potentially undermining investor confidence.
- Stock Price Plunge: Following Soleno's admission on November 4, 2025, of disruptions in DCCR's launch trajectory, the stock plummeted 27% in a single day, reflecting the market's deep concerns regarding the company's future prospects and operational viability.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share in cash, which may infringe on shareholder rights, prompting shareholders to understand their legal rights and options.
- Complex Transaction Terms: Thermon Group Holdings, Inc. (NYSE:THR) is proposed to be sold to CECO Environmental Corp., where shareholders can choose between $10.00 in cash plus 0.6840 shares of CECO stock, $63.89 per share, or 0.8110 shares of CECO stock, potentially affecting the final returns for shareholders.
- Cash Acquisition Proposal: Affinity Bancshares, Inc. (NASDAQ:AFBI) plans to sell to Fidelity BancShares (N.C.) for $23.00 per share in cash, subject to adjustments based on the adjusted stockholders' equity at closing, adding uncertainty to the transaction.
- Shareholder Rights Protection: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief measures to protect shareholder rights and address potential securities fraud issues.
See More
Multiple Companies Facing Class Action Lawsuits
- Eos Energy Lawsuit: Eos Energy Enterprises is facing allegations for failing to meet production and capacity utilization targets during the period from November 5, 2025, to February 26, 2026, which has severely undermined investor confidence and is expected to negatively impact its stock performance.
- Soleno Therapeutics Issues: Soleno Therapeutics is under scrutiny for concealing safety concerns related to its DCCR clinical trial from March 26, 2025, to November 4, 2026, potentially jeopardizing the commercial viability of its product and eroding investor trust and market performance.
- Nektar Therapeutics Allegations: Nektar Therapeutics faces accusations of not adhering to applicable standards in its REZOLVE-AA trial from February 26, 2025, to December 15, 2025, which may compromise the integrity of trial results and adversely affect the company's reputation and stock price.
- Driven Brands Financial Errors: Driven Brands is being sued for multiple financial reporting errors from May 3, 2023, to February 24, 2026, which could lead to a decline in investor confidence regarding the company's financial health, thereby impacting its market performance.
See More
Soleno Therapeutics Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns regarding its DCCR drug during clinical trials, including issues like fluid retention in participants, which led to investor losses once the true information was disclosed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong expertise and track record in this field.
- Investor Guidance: The firm advises investors to select counsel with proven success to avoid partnering with firms that merely act as intermediaries, ensuring they receive the best representation and support in the class action process.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Soleno Therapeutics in the Northern District of California on behalf of investors who purchased shares between March 26 and November 4, 2025, alleging the company failed to disclose safety concerns related to its DCCR drug, resulting in investor losses.
- Allegation Details: The complaint claims that Soleno systematically downplayed and concealed significant safety issues associated with DCCR, including fluid retention in trial participants, which materially affected the drug's commercial viability and posed greater risks than disclosed.
- Investor Losses: Investors suffered significant damages when the true details emerged, and the lawsuit seeks accountability from Soleno, with a deadline of May 5, 2026, for investors to apply to be lead plaintiffs in the case.
- Legal Consultation Opportunity: Bragar Eagel & Squire encourages affected investors to reach out for discussions about their legal rights, offering no-cost consultations to ensure investors understand their rights and potential legal avenues.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ:SLNO) is facing a securities class action lawsuit, with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26, 2025, and November 4, 2025, and suffered significant losses.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed safety risks associated with its flagship product, VYKAT™ XR (DCCR), and used questionable metrics to maintain an inflated stock price, resulting in investor losses.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 financial results, admitting to disruptions in DCCR's launch trajectory, leading to a 27% drop in stock price on the same day, reflecting market disappointment in the company's outlook.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% for original information that aids in the investigation, aiming to protect investor interests.
See More
